Summary: “Commercialization simply as profit maximization has raised a lot of tough questions about our ethics in the movement,” says Joy Sun Cooper, Chief of Patient Access and Head of Commercialization at MAPS Public Benefit Corporation (MAPS PBC), in The American Prospect.
“Millions of people could benefit from psychedelic-assisted therapy, if it’s approved,” writes author Luke Goldstein. “But a monopoly would put it all at risk.”
